Sutro Biopharma to Participate in the Jefferies Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in the Jefferies Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 31, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

News, Press Releases

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones – Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as...

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference SOUTH SAN FRANCISCO, Calif., May 8, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

News, Press Releases

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., April 27, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Events, News, Presentations, Press Releases

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023 ORLANDO, FL— April 18, 2023 — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering...

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

News, Press Releases

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones – Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter...